Omeros Corp
OMER6.590USD
+0.010+0.15%
Close 11/07, 16:00（ET）Quotes delayed by 15 min
395.55MMarket Cap
LossP/E TTM
More Details of Omeros Corp Company
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Company’s lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
Omeros Corp Info
Ticker SymbolOMER
Company nameOmeros Corp
IPO dateOct 08, 2009
CEODR. Gregory A. Demopulos, M.D.
Number of employees202
Security typeOrdinary Share
Fiscal year-endOct 08
Address201 Elliott Avenue West
CitySEATTLE
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code98119
Phone12066765000
Websitehttps://www.omeros.com/
Ticker SymbolOMER
IPO dateOct 08, 2009
CEODR. Gregory A. Demopulos, M.D.
Company Executives of Omeros Corp
Name
Name/Position
Position
Shareholding
Change
Dr. Peter A. Demopulos, M.D.
Dr. Peter A. Demopulos, M.D.
Director
Director
372.90K
--
Dr. Leroy E. Hood, M.D., Ph.D.
Dr. Leroy E. Hood, M.D., Ph.D.
Independent Director
Independent Director
74.39K
--
Mr. Thomas J. Cable
Mr. Thomas J. Cable
Lead Independent Director
Lead Independent Director
35.07K
--
Mr. Arnold C. Hanish, CPA
Mr. Arnold C. Hanish, CPA
Independent Director
Independent Director
12.40K
--
Dr. Mariana N. Dimitrova, Ph.D.
Dr. Mariana N. Dimitrova, Ph.D.
Vice President - Chemistry, Manufacturing and Controls
Vice President - Chemistry, Manufacturing and Controls
--
--
Mr. Peter B. Cancelmo, J.D.
Mr. Peter B. Cancelmo, J.D.
Vice President, General Counsel, Secretary
Vice President, General Counsel, Secretary
--
--
Dr. Thomas F. Bumol, Ph.D.
Dr. Thomas F. Bumol, Ph.D.
Independent Director
Independent Director
--
--
Dr. Catherine A. Melfi, Ph.D.
Dr. Catherine A. Melfi, Ph.D.
Vice President - Regulatory Affairs and Quality Systems, Chief Regulatory Officer
Vice President - Regulatory Affairs and Quality Systems, Chief Regulatory Officer
--
--
DR. Gregory A. Demopulos, M.D.
DR. Gregory A. Demopulos, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Mr. David J. Borges
Mr. David J. Borges
Chief Accounting Officer, Vice President - Finance, Treasurer
Chief Accounting Officer, Vice President - Finance, Treasurer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Peter A. Demopulos, M.D.
Dr. Peter A. Demopulos, M.D.
Director
Director
372.90K
--
Dr. Leroy E. Hood, M.D., Ph.D.
Dr. Leroy E. Hood, M.D., Ph.D.
Independent Director
Independent Director
74.39K
--
Mr. Thomas J. Cable
Mr. Thomas J. Cable
Lead Independent Director
Lead Independent Director
35.07K
--
Mr. Arnold C. Hanish, CPA
Mr. Arnold C. Hanish, CPA
Independent Director
Independent Director
12.40K
--
Dr. Mariana N. Dimitrova, Ph.D.
Dr. Mariana N. Dimitrova, Ph.D.
Vice President - Chemistry, Manufacturing and Controls
Vice President - Chemistry, Manufacturing and Controls
--
--
Mr. Peter B. Cancelmo, J.D.
Mr. Peter B. Cancelmo, J.D.
Vice President, General Counsel, Secretary
Vice President, General Counsel, Secretary
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Nov 8
Updated: Sat, Nov 8
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Ingalls & Snyder LLC (Asset Management)
6.03%
BlackRock Institutional Trust Company, N.A.
5.43%
The Vanguard Group, Inc.
4.92%
D. E. Shaw & Co., L.P.
2.42%
Stifel, Nicolaus & Company, Incorporated
2.24%
Other
78.96%
Shareholders
Shareholders
Proportion
Ingalls & Snyder LLC (Asset Management)
6.03%
BlackRock Institutional Trust Company, N.A.
5.43%
The Vanguard Group, Inc.
4.92%
D. E. Shaw & Co., L.P.
2.42%
Stifel, Nicolaus & Company, Incorporated
2.24%
Other
78.96%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
16.48%
Investment Advisor
15.58%
Hedge Fund
6.07%
Research Firm
3.82%
Individual Investor
2.90%
Bank and Trust
0.88%
Insurance Company
0.12%
Venture Capital
0.09%
Pension Fund
0.05%
Other
53.99%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
243
29.83M
43.83%
+1.23M
2025Q2
255
30.16M
44.94%
-422.08K
2025Q1
263
30.38M
51.89%
-522.27K
2024Q4
256
29.32M
50.59%
-441.66K
2024Q3
242
27.89M
48.13%
-1.92M
2024Q2
248
27.65M
47.72%
-3.10M
2024Q1
269
28.11M
48.16%
-3.03M
2023Q4
275
27.52M
43.79%
-6.21M
2023Q3
299
30.25M
48.14%
-4.77M
2023Q2
303
29.52M
46.99%
+306.67K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Ingalls & Snyder LLC (Asset Management)
3.98M
5.85%
+5.10K
+0.13%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.69M
5.43%
-328.94K
-8.18%
Jun 30, 2025
The Vanguard Group, Inc.
3.28M
4.82%
+46.32K
+1.43%
Jun 30, 2025
D. E. Shaw & Co., L.P.
1.65M
2.42%
-291.10K
-15.02%
Jun 30, 2025
Stifel, Nicolaus & Company, Incorporated
1.52M
2.24%
-33.76K
-2.17%
Jun 30, 2025
Demopulos (Gregory A. M.D.)
2.03M
2.98%
--
--
May 23, 2025
Geode Capital Management, L.L.C.
1.37M
2.01%
+739.00
+0.05%
Jun 30, 2025
State Street Investment Management (US)
1.20M
1.76%
-156.01K
-11.50%
Jun 30, 2025
Two Sigma Investments, LP
1.09M
1.61%
+971.88K
+802.28%
Jun 30, 2025
Morgan Stanley & Co. LLC
1.09M
1.6%
+501.25K
+85.73%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.48%
iShares Micro-Cap ETF
0.05%
Invesco Nasdaq Biotechnology ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.03%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 ETF
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Growth ETF
0.01%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0.48%
iShares Micro-Cap ETF
Proportion0.05%
Invesco Nasdaq Biotechnology ETF
Proportion0.03%
ProShares Ultra Nasdaq Biotechnology
Proportion0.03%
ProShares UltraPro Russell2000
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
iShares Russell 2000 Growth ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
